Multimodal Analgesia

SHELBY HARRIS, MD

ATRIUM HEALTH WAKE FOREST BAPTIST MEDICAL CENTER

ASSISTANT PROFESSOR - DEPARTMENT OF ANESTHESIOLOGY

SECTION ON REGIONAL ANESTHESIA AND ACUTE PAIN MANAGEMENT

Disclosures

No financial disclosures or conflicts of interest

Outline

Background of Perioperative Pain

Pathophysiology of pain

Types of Analgesics

Strategies for Perioperative Pain Control

Multimodal Postoperative Pain Control After Orthopaedic Surgery

Gabriel Sampognaro ¹, Richard Harrell ²

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. 2023 Jan 29.

Affiliations + expand PMID: 34283438 Bookshelf ID: NBK572072 Free Books & Documents

Excerpt

Multimodal Analgesia (MMA), also referred to as "balanced analgesia," uses multiple analgesic medications, physical modalities, and cognitive strategies to affect peripheral and central nerve loci for the treatment of pain. In light of the adverse side effects of opioid medication, the MMA model of pain management allows physicians an array of medicine and other modalities to help decrease the morbidity associated with opioid analgesics often used as monotherapy. The number of drug overdoses continues to rise every year, with opioids accounting for nearly two-thirds of the cases and being the leading cause of accidental death in the United States. Orthopedic surgeons are attributed to writing 7.7% of all opioid prescriptions while only accounting for 2.5% of all prescribing physicians

Orthopedic surgeons are challenged with the task of pain management while mitigating the risk associated with opioids. MMA allows orthopedic surgeons and other medical professionals a more modern and evidence-based approach in treating acute pain in their patients. The use of NSAIDs, acetaminophen, gabapentinoids, immediate-release opioids, cognitive therapy, peri-articular injections, and physical modalities, such as cryotherapy, will be reviewed in this article to assist the modern orthopedic surgeon in controlling pain in their patients in the postoperative period. In addition, this article will review the various drug classes, adverse effects, and contraindications and provide insight into special consideration to certain patients who are opioid-tolerant or suffer from comorbid conditions.

Copyright © 2023, StatPearls Publishing LLC.

Review > Clin Podiatr Med Surg. 2019 Oct;36(4):695-705. doi: 10.1016/j.cpm.2019. Epub 2019 Jul 27.

Opioid Crisis and Acute Pain Management After Foot and Ankle Surgery

Melinda A Bowlby ¹, Mary E Crawford ²

Affiliations + expand PMID: 31466576 DOI: 10.1016/j.cpm.2019.06.009

Abstract

Opioid abuse has plagued the United States, with a resurgence since the early 2000s. Governmental agencies, pharmaceutical companies, patients, and physicians have all contributed to this crisis. Severe pain has been reported following foot and ankle surgery. There are current national guidelines for chronic opioid prescribing, but guidelines for acute pain have not been established. Prescribing fewer opioids, education on opioid risks, proper disposal of unused medication, and participating in prescription monitoring programs help reduce opioid abuse. Multimodal analgesia is paramount in managing pain while reducing opioid consumption after postoperative foot and ankle surgery.

Keywords: Ankle; Foot; Multimodal; Opioids; Pain; Surgery.

Copyright © 2019 Elsevier Inc. All rights reserved.

<u>Korean J Anesthesiol.</u> 2018 Oct; 71(5): 345–352. Published online 2018 Aug 24. doi: <u>10.4097/kja.d.18.00217</u> PMCID: PMC6193589 PMID: <u>30139215</u>

Designing the ideal perioperative pain management plan starts with multimodal analgesia

Eric S. Schwenk¹ and Edward R. Mariano^{2,3}

► Author information ► Article notes ► Copyright and License information Disclaimer

Abstract

Multimodal analgesia is defined as the use of more than one pharmacological class of analgesic medication targeting different receptors along the pain pathway with the goal of improving analgesia while reducing individual class-related side effects Evidence today supports the routine use of multimodal analgesia in the perioperative period to eliminate the over-reliance on opioids for pain control and to reduce opioid-related adverse events. A multimodal analgesic protocol should be surgery-specific, functioning more like a checklist than a recipe, with options to tailor to the individual patient. Elements of this protocol may include opioids, non-opioid systemic analgesics like acetaminophen, non-steroidal anti-inflammatory drugs, gabapentinoids, ketamine, and local anesthetics administered by infiltration, regional block, or the intravenous route. While implementation of multimodal analgesic protocols perioperatively is recommended as an intervention to decrease the prevalence of long-term opioid use following surgery, the concurrent crisis of drug shortages presents an additional challenge. Anesthesiologists and acute pain medicine specialists will need to advocate locally and nationally to ensure a steady supply of analgesic medications and in-class alternatives for their patients' perioperative pain management.

Keywords: Acute pain management, Ketamine, Multimodal analgesia, Non-opioid analgesics, Opioid epidemic, Regional anesthesia

Go to: 🕨

The Numbers

80% of patients experience acute post-op pain

75% rate it as moderate – extreme

Less than 50% report satisfaction with pain control

Poor acute pain control post-op has been linked to persistent/chronic pain (Lancet 2006)

Goals

Perioperative pain control while maintaining motor function

- Physical Therapy
- Occupational Therapy

Decrease Opioid Consumption

- Return of Bowel Function
- Cognitive fog, sedation
- We have an opioid problem



Pathophysiology of Pain

Acute

- In response to tissue injury
- A-delta and C sensory fibers (nociceptors)

Chronic


- Persistent activation of these fibers
- Ongoing damage or dysfunction of PNS or CNS > neuropathic pain

Nociceptive

- Pain caused by tissue injury
- Somatic (skin, subcutaneous tissue, fascia, periosteum, joint capsules, etc). Normally sharp or dull localized pain or burning
- Visceral (viscera and surrounding connective tissues). Poorly localized, deep, sometimes cramping; occasionally localized due to nature of injury (organ capsule, etc)

Psychologic factors

- Chronic pain oftentimes associated with psychological distress, depression, anxiety
- Many pain syndromes are multifactorial; (ie, nociceptive + neuropathic)



American Pain Society (APS)



The Journal of Pain Volume 17, Issue 2, February 2016, Pages 131-157



Guidelines on the Management of Postoperative Pain

Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council

 Roger Chou *
 Q
 M, Debra B. Gordon[†], Oscar A. de Leon-Casasola[‡], Jack M. Rosenberg[§],

 Stephen Bickler
 ¶, Tim Brennan^{II}, Todd Carter **, Carla L. Cassidy^{††}, Eva Hall Chittenden^{‡‡},

 Ernest Degenhardt[®], Scott Griffith
 ¶¶, Renee Manworren^{III}, Bill McCarberg ***,

 Robert Montgomery^{†††}, Jamie Murphy^{‡‡‡‡}, Melissa F. Perkal[®], Santhanam Suresh
 ¶¶¶,

 Kathleen Sluka^{IIIII}, Scott Strassels ****, Richard Thirlby^{††††}...Christopher L. Wu^{‡‡‡‡}

Show more 🗸

Treatment of pain

Non opioid analgesics – Acetaminophen, NSAIDs

Antidepressants – TCAs, SNRIs

Gabapentinoids – Gabapentin, Pregabalin

Muscle Relaxants

Opioid analgesics

Glucocorticoids (intraoperative)

NMDA receptor antagonist (intraoperative)

Alpha 2 agonists (intraoperative)

Neuraxial – opioid pumps, spinal cord stimulators

Nerve blocks

Cognitive behavioral therapy

Integrative medicine techniques – acupuncture, relaxation techniques, biofeedback, etc.

Nonopioid analgesics: Acetaminophen and NSAIDs

Effective for mild to moderate pain. Act synergistically along with opioids

Acetaminophen: Not anti-inflammatory or antiplatelet; no gastric irritation

- Caution in patients with liver dysfunction
- Maximum of 4g/day, or 1,000 mg QID

NSAIDs: analgesic, anti-inflammatory, antiplatelet

- Inhibit COX enzymes and; therefore, prostaglandin production
 - Non-selective COX inhibitors ibuprofen, naproxen
 - Semiselective meloxicam (Mobic)
 - Selective COX-2 inhibitors- celecoxib lower risk of ulcer formation and GI upset
 - All are prothrombotic MI, stroke claudication risk
 - Caution in patients with renal dysfunction
 - Topical NSAIDs diclofenac; patch or gel

Review > Neuropharmacology. 2019 Nov 1;158:107619. doi: 10.1016/j.neuropharm.2019.04.025. Epub 2019 Apr 25.

Combining opioids and non-opioids for pain management: Current status

Jun-Xu Li 1

Affiliations + expand PMID: 31029588 DOI: 10.1016/j.neuropharm.2019.04.025

Abstract

Pain remains a global health challenge. For decades, clinicians have been primarily relying on μ -opioid receptor (MOR) agonists and nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management. MOR agonists remain the most efficacious analgesics available; however, adverse effects related to MOR agonists use are severe which often lead to forced drug discontinuation and inadequate pain relief. The recent opioid overdose epidemic urges the development of safer analgesics. Combination therapy is a well-established clinical pharmacotherapeutic strategy for the treatment of various clinical disorders. The combination of MOR agonists with non-MOR agonists may increase the analgesic potency of MOR agonists, reduce the development of tolerance and dependence, reduce the diversion and abuse, overdose, and reduce other clinically significant side effects associated with prolonged opioid use such as constipation. Overall, the combination therapy approach could substantially improve the therapeutic profile of MOR agonists. This review summarizes some recent developments in this field. This article is part of the Special Issue entitled 'New Vistas in Opioid Pharmacology'.

Keywords: Abuse liability; Antagonists; Combination therapy; Opioids; Pain; Tolerance.

Copyright © 2019 Elsevier Ltd. All rights reserved.

Class	Drug	Usual Dosage Range*		
	Diclofenac	50–100 mg, followed by 50 mg every 8 hours 75 mg every 12 hours IV or IM		
Indoles	<u>Etodolac</u>	200-400 mg every 6-8 hours		
	Indomethacin	25-50 mg every 6-8 hours		
	Sulindac	150-200 mg every 12 hours		
	Tolmetin	200-400 mg every 6-8 hours		
Naphthylalkanone	Nabumetone 1000–2000 mg every 24 hours			
Dxicam	Piroxicam	20-40 mg every 24 hours		
ara-aminophenol erivative	Acetaminophen	650–1000 mg every 6-8 hours		
ropionic acids	<u>Fenoprofen</u>	200-600 mg every 6 hours		
	Flurbiprofen	50-200 mg every 12 hours		
	Ibuprofen†	400 mg every 4 hours to 800 mg every 8 hours (maximum: 3200 mg/day†)		
	<u>Ketoprofen</u>	25-50 mg every 6-8 hours		
	<u>Naproxen</u>	250-500 mg every 12 hours		
	Naproxen sodium	275-550 mg every 12 hours		

* Route is oral, except for <u>ibuprofen</u>, <u>ketorolac</u>, <u>diclofenac</u>, and <u>acetaminophen</u>, which can be given parenterally as well as orally. There is a topical form of <u>diclofenac</u>.

† For <u>ibuprofen</u>, dosages ≤ 2400 mg reduce cardiovascular risk and are recommended for patients with cardiovascular risk factors.

COX = cyclooxygenase.

Class	Drug	Usual Dosage Range*		
	Oxaprozin	600-1200 mg every 24 hours		
	Aspirin	650–1000 mg every 4–6 hours		
Salicylates	Choline magnesium trisalicylate	870 mg every 12 hours		
	Diflunisal	250–500 mg every 8–12 hours		
	Salsalate	750–2000 mg every 12 hours		
F	Meclofenamate	50–100 mg every 6–8 hours		
Fenamates	Mefenamic acid	250 mg every 6 hours		
Pyrazole	Phenylbutazone	100 mg every 6–8 hours up to 7 days		
Pyrrolo-pyrrolo Ketorolac or derivative cr		15–30 mg IV or IM every 6 hours or 20 mg orally, followed by 10 mg orally every 4–6 hours for maximum 5 days (assess creatinine every 4–6 doses, particularly in patients who are older or at risk of renal failure [eg, postoperative patients])		
Selective COX-2 inhibitor	Celecoxib	100-200 mg every 12 hours		
		lac, <u>diclofenac</u> , and <u>acetaminophen</u> , which here is a topical form of <u>diclofenac</u> .		
† For ibuprofen, dos patients with cardiov		cardiovascular risk and are recommended for		
	se.			

MERCK

© 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.



Muscle Relaxants

Tizanidine (Zanaflex): alpha-2 agonist – CNS and anxiolysis; drowsiness, hypotension, QT prolongation

Cyclobenzaprine (Flexeril): 5-HT2 receptor antagonist; dizziness, tachycardia

Methocarbamol (Robaxin): RAS?; least sedating muscle relaxant; IV formulation should not be used in patient's with renal dysfunction (polyethelene glycol > worsening of acidosis)

Baclofen: GABA analog; spasticity; withdrawal common upon cessation

Diazepam (Valium): positive allosteric modulators of the GABA type A receptors; anxiolytic; sedation

Caution in elderly

Muscle spasms common after orthopedic surgery; "cramping, pulling, tight"

Opioid analgesics

Proven efficacy for acute pain, cancer-related pain, and as part of palliative care

Generally, short-acting (immediate release) agonists are used for acute pain at the lowest effective dose

- CDC recommends 3-7 days; patient's should be reevaluated before re-prescribing opioids
- Long-duration and high dose opioid use increases risk of adverse effects and opioid misuse
- Patient's should be transitioned off of opioids (and continued on multimodals) ASAP after trauma/surgery

Adverse effects

• opioid use disorder, overdose, respiratory depression, somnolence, nausea/vomiting, constipation

Opioid analgesics

Physical dependence should be assumed in all patients on opioids for more than a few days

- Withdrawal symptoms; taper off; use as little as possible
- Physical dependence is not the same as opioid use disorder, which involves compulsive use, loss of control, craving, etc.

Tolerance develops in all patients treated with opioids

Decreased response to same dose of a drug when used repeatedly

Can consider opioid agonists-antagonists, especially in patients with OUD or history of addiction instead of pure opioid agonists (buprenorphine)

- Patient will receive analgesic benefit without the "high" associated with pure opioid agonists
- Have a ceiling effect for analgesia; be aware that they will precipitate withdrawal in a patient already physically dependent on opioids

Opioid analgesics: Dosing and titration

Opioid naïve patient

- start at the lowest available starting dose of IR formulation and increase incrementally as tolerated by patient until adequate analgesic or dose-limiting side effects
- Combination drugs (Norco, Percocet) opioid dose may become limited by acetaminophen dose
- Older patients more sensitive
- Do not start with a long-acting narcotic (oxycontin) in an opioid naïve patient; prone to adverse effects
- Can consider PCA if patient unable to take medications orally

Opioid tolerant patient

• Will require ~ 2x amount of narcotic on at baseline (anecdotal)

Caution in patients with hepatic disorders, COPD, OSA, dementia (delirium), renal insufficiency (fentanyl and methadone metabolites)

- Caution in co-administering with benzodiazepines
- Always have naloxone available

Initial PO opioid dosing ranges (naiive)

Common dosage range: <u>Oxycodone</u> 2.5-15 mg PO q4h PRN				
Elderly or high-risk2.5-5 mg PO q4h PRN (starting dose)				
Young, low-risk 5-10 mg PO q4h PRN (starting dose)				

Common dosage range: <u>Hydromorphone</u> 1-6 mg PO q4h PRN				
Elderly or high-risk1-2 mg PO q4h PRN (starting dose)				
Young, low-risk	2-4 mg PO q4h PRN (starting dose)			

Initial breakthrough IV dosage

Common dosage range: <u>Hydromorhone</u> 0.2-1 mg PO q4h PRN				
Elderly or high-risk0.2 mg IV q2h PRN (starting dose)				
Young, low-risk	0.4 mg IV q2h PRN (starting dose)			

Common dosage range: <u>Morphine</u> 1-5 mg PO q4h PRN				
Elderly or high-risk1 mg IV q2h PRN (starting dose)				
Young, low-risk	2 mg IV q2h PRN (starting dose)			

Methadone Oral: 2.5-10 mg every 8-12 hours Parenteral: 2.5-10 mg IM or IV every 8-12 hours

plogic-disorder

Adult Dose*

Oral

immediate-

mg every 4

hours

release: 5-30

Oral controlled-

release: 15 mg

every 12 hours

Oral sustained-

release: 30 mg

every 24 hours

mg IV or IM

as needed

Adult Dose*

Oral: 5-10 mg every 6 hours

Oral controlled-

release: 10-20

mg every 12

hours

//www.merckmanuals.com/professional/neurologic-disorders/pail

Parenteral: 2-5

every 2-4 hours

8:09 AM

Drug

Morphine

3,8:09 AM

Drug

Oxycodone‡

heroin withdrawal, long-term maintenance

Pediatric Dose†

> 6 months old and

· Oral immediate-

release tablet or oral solution:

< 50 kg:

0.2-0.5 mg/kg/dose every

3-4 hours as

dose 15-20

IV (preferred),

IM (IM not

subcutaneous.

recommended):

0.05 mg/kg/dose

every 2-4 hours

as needed (initial

maximum dose

1-2 mg/dose)

> 6 months old and

· Oral immediate-

release tablets or oral solution: 15-20 mg every 3-4 hours as needed. Parenteral (IV, subcutaneous, or IM): 2-5 mg/dose every 2-4 hours as needed

≥ 50 kg:

ment-of-pain

Treatment of Pain - Neurologic Disorders - Merck Manuals Professional Edition

Comments

<u>aspirin</u>

Also in combination

products containing

acetaminophen or

Pediatric Dose†

mg/dose)

needed (usual

initial maximum

_

Opioid Analgesics

Drug	Adult Dose*	Pediatric Doset	Comments
Opioid agonists	in combination product	s‡ for moderate pain	
Codeine	Oral: 30–60 mg every 4–6 hours as needed	-	Less potent than morphine
Hydrocodone	Oral: 5–10 mg every 4–6 hours as needed	-	More potent than codeine

Opioid agonists for moderate-to-severe pain

<u>Fentanyi</u>	Transdermal: 12 or 25 mcg/hour every 3 days Transmucosal: 100-200 mcg every 2-4 hours Intransal: 100- 200 mcg every 2-4 hours Parenteral: 25- 100 mcg every 30-60 minutes IV or as patient- controlled analgesia	Parenteral: 1-2 mcg/kg/dose IV; may be repeated in 2-4 hours as needed	May trigger less histamine release and thus may cause less hypotension than other opioids Transdermal: When used in cachectic patients, may result in erratic absorption and blood levels Supplemental analgesia required at first because peak analgesia does not occur until 18–24 hours after application May take many hours for adverse effects to resolve after removing patch Short-acting transmucosal and intranasal forms: Used for breakthrough pain in opioid-tolerant adults
s://www.menckmanualis.com/	orofessionalineurologic-disorders/pain	freatment-of-pain	breakthrough pain in
23, 8:09 AM	Treatment of Pain -	Neurologic Disorders - Merck Manua	is Professional Edition
Drug	Adult Dose*	Pediatric Dose†	Comments
			and for conscious sedation in children IV form: Sometimes used for procedural sedation
	Oral immediate release: 2-4 mg every 4-6 hours Oral extended- release: 8-32 mg every 24		

treatment of opioid use disorder, and analgesia for chronic pain Establishment of a safe, effective dose for analgesia complicated by its long half-life (usually much longer than duration of analgesia) Requires close monitoring for several days or more after amount or frequency of dose is increased because serious toxicity can occur as the plasma level rises to steady

Used for treatment of

every 12 hours state for \geq 4 days, then increased to 150 mcg every 12 hours Transdermal patch: initially Treatment of Pain - Neurologic Disorders - Merck Manuals Professional Edition 5mcg/hour Comments Risk of QT-interval prolongation; ECG monitoring W recommended 1, 8:09 AM Drug 1 Standard of comparison Triggers histamine release more often than other opioids. causing itching

Opioid agonist-antagonists§

Buprenorphine

IV or IM: 0.3 mg

every 6 hours

Sublingual: 75

mcg once a day

or, if tolerated,

Smcg/hour applied once a week; may be titrated to 20 mcg/hour once a week		analgesics (eg. morphine. [entanyl) but not fully reversible with <u>naloxane</u> Higher affinity for mu receptors than traditional analgesics
naliheurologic-disorders/pai	ntreatment-of-pain	
Treatment of Pair	- Neurologic Disorders - Merck Manua	is Professional Edition
Adult Dose*	Pediatric Doset	Comments
		May induce acute withdrawali if added to long-term opioid therapy Analgesic effect of traditional analgesics possibly limited when they are added to long-term therapy with <u>buprenorphine</u> Sublingual and transdermal <u>buprenorphine</u> used occasionally for <u>chronic pain</u> May be used as agonist therapy in <u>opioid use disorder</u> but requires special licensure

Use only in patients

> 13 years (same as

adult dose)

Psychotomimetic

sedation) less

of other agonist-

antagonists, but

depression with

with traditional

buprenorphine than

Lower risk of

respiratory

other effects similar

effects (eg, delirium,

prominent than those

Tramadol Oral Not recommended Less potential for immediate abuse than with release: 50-100 other opioids mg every 4-6 Not as potent as other opioid hours; maximum 400 mg/day analgesics Oral extendedrelease: 100 mg once a day; increase by ≤ 100 mg/day every 5 days to a c//www.merckmanuals.com/profes 13, 8:09 AM Treatment of Pain - Neurologic Disorders - Merck Manuals Professional Edition Drug Adult Dose* Pediatric Doset Comments dose of ≤ 300 mg total daily dose * Starting doses are for opioid-naive patients. Patients with opioid tolerance or severe pain may require higher doses. 1 Not all drugs are appropriate for analgesia in children. ‡ These opioid agonists may be combined into a single pill with acetaminophen, aspirin, or ibuprofen. They are often used alone so that acetaminophen, aspirin, or ibuprofen dosing limits do not limit opioid dosing. If combination therapy is desired, acetaminophen, aspirin, or ibuprofen can be added separately while maximizing flexibility in dosing the opioid agonist. § Opioid agonist-antagonists are not usually used for chronic pain and are rarely drugs of choice for older patients. © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. MERCK MERCK MANUAL

MERCK MANUAL Professional Version


Buprenorphine

Chronic pain

- Likely high opioid tolerance and hypersensitivity to pain
- Transdermal, buccal
- Can consider adding direct-acting agonists

MAT

- High risk of relapse with direct-act opioid agonists
- Sublingual, IM depot, subdermal
- Continue home dose and add
- Doses >24 mg/day, no benefit



Review > Reg Anesth Pain Med. 2021 Oct;46(10):840-859. doi: 10.1136/rapm-2021-103007. Epub 2021 Aug 12.

Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel

Lynn Kohan ¹¹, Sudheer Potru ²² ¹³, Antje M Barreveld ⁴⁰, Michael Sprintz ¹⁵, Olabisi Lane ¹⁵, Anuj Aryal ¹⁷, Trent Emerick ⁴¹, Anna Dopp ¹⁹, Sophia Chhay ¹⁹, Eugene Viscusi ³⁰

Affiliations + expand PMID: 34385292 DOI: 10.1136/rapm-2021-103007

Abstract

Background: The past two decades have witnessed an epidemic of opioid use disorder (OUD) in the USA, resulting in catastrophic loss of life secondary to opioid overdoses. Medication treatment of opioid use disorder (MOUD) is effective, yet barriers to care continue to result in a large proportion of untreated individuals. Optimal analgesia can be obtained in patients with MOUD within the perioperative period. Anesthesiologists and pain physicians can recommend and consider initiating MOUD in patients with suspected OUD at the point of care; this can serve as a bridge to comprehensive treatment and ultimately save lives.

Methods: The Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiologists, American Academy of Pain Medicine, American Society of Addiction Medicine and American Society of Health System Pharmacists approved the creation of a Multisociety Working Group on Opioid Use Disorder, representing the fields of pain medicine, addiction, and pharmacy health sciences. An extensive literature search was performed by members of the working group. Multiple study types were included and reviewed for quality. A modified Delphi process was used to assess the literature and expert opinion for each topic, with 100% consensus being achieved on the statements and each recommendation. The consensus statements were then graded by the committee members using the United States Preventive Services Task Force grading of evidence guidelines. In addition to the consensus recommendations, a narrative overview of buprenorphine, including pharmacology and legal statutes, was performed.

Results: Two core topics were identified for the development of recommendations with >75% consensus as the goal for consensus; however, the working group achieved 100% consensus on both topics. Specific topics included (1) providing recommendations to aid physicians in the management of patients receiving buprenorphine for MOUD in the perioperative setting and (2) providing recommendations to aid physicians in the initiation of buprenorphine in patients with suspected OUD in the perioperative setting.

Conclusions: To decrease the risk of OUD recurrence, buprenorphine should not be routinely discontinued in the perioperative setting. Buprenorphine can be initiated in untreated patients with OUD and acute pain in the perioperative setting to decrease the risk of opioid recurrence and death from overdose.

Keywords: analgesics; opioid; opioid-related disorders; pain; pain management; pharmacology; postoperative.

Adjuvant medications – Gabapentinoids, TCAs, SNRIs

Can relieve pain, specifically pain with a neuropathic component

TCAs: amitriptyline, nortriptyline

• Blocks reuptake of serotonin and NE

SNRIs : duloxetine

• Serotonin and NE reuptake inhibitor

Gabapentinoids Gabapentin, Pregabalin (Lyrica)

 side effects may outweigh benefits; exceptions for patients on chronic gabapentinoid therapy Review > Neuroscience. 2016 Dec 3;338:183-206. doi: 10.1016/j.neuroscience.2016.06.057. Epub 2016 Jul 9.

Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights

Mélanie Kremer¹, Eric Salvat², André Muller², Ipek Yalcin³, Michel Barrot⁴


Affiliations + expand PMID: 27401055 DOI: 10.1016/j.neuroscience.2016.06.057

Abstract

Neuropathic pain arises as a consequence of a lesion or disease affecting the somatosensory system It is generally chronic and challenging to treat. The recommended pharmacotherapy for neuropathic pain includes the use of some antidepressants, such as tricyclic antidepressants (TCAs) (amitriptyline. or serotonin and noradrenaline re-uptake inhibitors (duloxetine...), and/or anticonvulsants such as the gabapentinoids gabapentin or pregabalin. Antidepressant drugs are not acute analgesics but require a chronic treatment to relieve neuropathic pain, which suggests the recruitment of secondary downstream mechanisms as well as long-term molecular and neuronal plasticity. Noradrenaline is a major actor for the action of antidepressant drugs in a neuropathic pain context. Mechanistic hypotheses have implied the recruitment of noradrenergic descending pathways as well as the peripheral recruitment of noradrenaline from sympathetic fibers sprouting into dorsal root ganglia; and importance of both α^2 and β^2 adrenoceptors have been reported. These monoamine re-uptake inhibitors may also indirectly act as anti-proinflammatory cytokine drugs; and their therapeutic action requires the opioid system, particularly the mu (MOP) and/or delta (DOP) opioid receptors. Gabapentinoids, which target the voltage-dependent calcium channels a26-1 subunit, inhibit calcium currents, thus decreasing the excitatory transmitter release and spinal sensitization. Gabapentinoids also activate the descending noradrenergic pain inhibitory system coupled to spinal α2 adrenoceptors. Gabapentinoid treatment may also indirectly impact on neuroimmune actors, like proinflammatory cytokines. These drugs are effective against neuropathic pain both with acute administration at high dose and with repeated administration. This review focuses on mechanistic knowledge concerning chronic antidepressant treatment and gabapentinoid treatment in a neuropathic pain context.

Keywords: antidepressants; gabapentinoids; monoaminergic system; neuroimmune; neuropathic pain; opioidergic system.

Volume 133, Issue 2 August 2020



Perioperative Medicine | August 2020

Perioperative Use of Gabapentinoids for the Management of Postoperative Acute Pain: A Systematic Review and Meta-analysis

FREE

Michael Verret, M.D., M.Sc.; François Lauzier, M.D., M.Sc.; Ryan Zarychanski, M.D., M.Sc.; Caroline Perron, M.Sc.; Xavier Savard, M.D. candidate; Anne-Marie Pinard, M.D., M.Sc.; Guillaume Leblanc, M.D., M.Sc.; Marie-Joëlle Cossi, Ph.D.; Xavier Neveu, M.Sc.; Alexis F. Turgeon, M.D., M.Sc. ... Show more

+ Author and Article Information

Anesthesiology August 2020, Vol. 133, 265-279.

https://doi.org/10.1097/ALN.00000000003428

Results

In total, 281 trials (N = 24,682 participants) were included in this meta-analysis. Compared with controls, gabapentinoids were associated with a lower postoperative pain intensity (100-point scale) at 6 h (mean difference, -10; 95% Cl, -12 to -9), 12 h (mean difference, -9; 95% Cl, -10 to -7), 24 h (mean difference, -7; 95% Cl, -8 to -6), and 48 h (mean difference, -3; 95% Cl, -5 to -1). This effect was not clinically significant ranging below the minimally important difference (10 points out of 100) for each time point. These results were consistent regardless of the type of drug (gabapentin or pregabalin). No effect was observed on pain intensity at 72 h, subacute and chronic pain. The use of gabapentinoids was associated with a lower risk of postoperative nausea and vomiting but with more dizziness and visual disturbance.

Conclusions

No clinically significant analgesic effect for the perioperative use of gabapentinoids was observed. There was also no effect on the prevention of postoperative chronic pain and a greater risk of adverse events. These results do not support the routine use of pregabalin or gabapentin for the management of postoperative pain in adult patients.

			ip to main content			
Drugs for Neur	opathic Pain			10–25 mg at bedtime (starting dose),	Dosing goal: About 100 mg/day (dosing for pain unlikely to be adequate for relieving depression or anxiety)	
Class/Drug Dose*	Dose*	Comments	Amitriptyline	increased weekly by the same dose to a maximum of 150 mg at bedtime	Not recommended for older patients or patients with a heart	
Antiseizure drugs†					disorder because it has strong anticholinergic effects	
		Monitor CBC and liver function during treatment			May increase dose to 150 mg or sometimes higher	
<u>Carbamazepine</u>	200–400 mg twice a day	May decrease efficacy of oral contraceptives First-line treatment for <u>trigeminal</u> <u>neuralgia</u>	Desipramine or nortriptyline	10–25 mg at bedtime (starting dose), increased weekly by the same dose to maximum of 150 mg at bedtime	Better tolerated than <u>amitriptyline</u> ; adverse effect profile better with desipramine than <u>nortriptyline</u> Dosing goal: About 100 mg/day (dosing for pain unlikely to be adequate for relieving depression or anxiety) Not recommended for older patients or patients with a heart disorder because it has strong anticholinergic effects	
<u>Gabapentin</u>	300–1200 mg 3 times a day	Starting dose usually 300 mg once a day Dosing goal: 600–1200 mg 3 times a day Adjust dose in patients with renal insufficiency				
		Starting dose usually 300 mg once a day Considered as efficacious as		* Route is oral unless otherwise indicated. † Topical <u>lidocaine</u> 4–5% applied 1 hour before applying <u>capsaicin</u> can help limit irritation.		
Oxcarbazepine	600–1200 mg twice a day	<u>carbamazepine</u> for trigeminal neuralgia and useful for other paroxysmal neuropathic pain May cause hyponatremia or decrease efficacy of oral contraceptives	CBC = complete blood count; EMLA = eutectic mixture of local anesthetics; GABA = gamma-aminobutyric acid; NMDA = <i>N</i> -methyl-p-aspartate; WBCs = white blood cells.			
			www.merckmanuals.com/profession	nal/neurologic-disorders/pain/treatment-of-pair	u#v1032795	
		Unlike <u>carbamazepine</u> , no CBC or liver function monitoring necessary	8:26 AM	Treatment of Pain - Neurologic Disc	rders - Merck Manuals Professional Edition	
Phenytoin	300 mg once a day	Limited data; 2nd-line drug	Class/Drug	Dose*	Comments	
Pregabalin	150-300 mg twice a	Mechanism similar to gabapentin			May increase dose to 150 mg or sometimes higher	
* Route is oral unless	day otherwise indicated.	but more stable pharmacokinetics		20–60 mg once a day (starting dose)		
† Topical lidocaine 4-	5% applied 1 hour before app	plying capsaicin can help limit irritation.		Starting at 20–30 mg once a day and	Better tolerated than tricyclic	
CBC = complete blood count; EMLA = eutectic mixture of local anesthetics; GABA = gamma-aminobutyric acid; NMDA = <i>N</i> -methyl-p-aspartate; WBCs = white blood cells.		Duloxetine	increasing by the same dosage weekly to a goal of 60 mg/day; in some cases, increasing to 60 mg twice a day	antidepressants Dosing goal for pain (60 mg/day) usually sufficient to treat concomitant depression or anxiety		

Antidepressants

(especially in patients with concomitant depression or anxiety)

Nerve blocks

Interrupt nerve transmission in peripheral or central pain pathways

Can be performed before or after procedure

Must determine appropriate type of block, intended length of duration, appropriate drug and dosage, and manage side effects (motor block, LAST)

Consider for hig pain-score surgeries

Typical preop regimen:

Regional technique (if amenable)
Acetaminophen 1000 mg PO
Celecoxib 400 mg PO
Methocarbamol 500 mg PO

Typical postop regimen:

Regional technique (nerve block) Acetaminophen 1000 mg PO q6h Celecoxib 200 mg PO BID Methocarbamol 500 mg PO QID Oxycodone 5-10 mg PO q4h PRN

Take Home

Use Multimodal Analgesia (Acetaminophen, NSAIDS, muscle relaxants, antidepressants)

Have multiple tools in your belt (regional techniques, familiarity with several classes of medications and know their side effects/contraindications)

Use Opioids as a supplement and wean off as soon as is appropriate

Phew! Questions?



References

Schwenk ES, Mariano ER. Designing the ideal perioperative pain management plan starts with multimodal analgesia. Korean J Anesthesiol. 2018 Oct;71(5):345-352. doi: 10.4097/kja.d.18.00217. Epub 2018 Aug 24. PMID: 30139215; PMCID: PMC6193589.

Sampognaro G, Harrell R. Multimodal Postoperative Pain Control After Orthopaedic Surgery. 2023 Jan 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 34283438.

Bowlby MA, Crawford ME. Opioid Crisis and Acute Pain Management After Foot and Ankle Surgery. ClinPodiatr Med Surg. 2019 Oct;36(4):695-705. doi: 10.1016/j.cpm.2019.06.009. Epub 2019 Jul 27. PMID: 31466576.

Li JX. Combining opioids and non-opioids for pain management: Current status. Neuropharmacology. 2019 Nov 1;158:107619. doi: 10.1016/j.neuropharm.2019.04.025. Epub 2019 Apr 25. PMID: 31029588.

Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. ExpertOpin Pharmacother. 2010 Dec;11(17):2813-25. doi: 10.1517/14656566.2010.507192. Epub 2010 Jul 19. PMID: 20642317.

Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience. 2016 Dec 3;338:183-206. doi: 10.1016/j.neuroscience.2016.06.057. Epub 2016 Jul 9. PMID: 27401055.

https://www.merckmanuals.com/professional/neurologic-disorders/pain/treatment-of-pain

Kohan L, Potru S, Barreveld AM, Sprintz M, Lane O, Aryal A, Emerick T, Dopp A, Chhay S, Viscusi E. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021 Oct;46(10):840-859. doi: 10.1136/rapm-2021-103007. Epub 2021 Aug 12. PMID: 34385292.

Quaye AN, Zhang Y. Perioperative Management of Buprenorphine: Solving the Conundrum. Pain Med. 2019 Jul 1;20(7):13951408. doi: 10.1093/pm/pny217. PMID: 30500943; PMCID: PMC7963209.